5 Best Diagnostics and Research Stocks to Buy According to Analysts

2. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Hedge Fund Holders: 113

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 best diagnostics and research stocks to buy according to analysts.

On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will evaluate the drug as a treatment for late-stage pancreatic cancer. It will utilize the Phase 2 results from the ongoing DURIPANC trial conducted with AstraZeneca. As pancreatic cancer remains a high-priority unmet medical need, AIM believes this strategic collaboration with Thermo Fisher Scientific Inc. (NYSE:TMO) offers the greatest growth potential for its stockholders.

Separately, on March 11, 2026, U.S. President Donald Trump announced a visit to Thermo Fisher Scientific Inc. (NYSE:TMO) in Ohio. Trump highlighted the company’s $2 billion investment in U.S. manufacturing and credited it to his “America First” trade and tariff policies. The investment will potentially repatriate high-paying jobs and strengthen domestic supply chains.

As of March 21, 2026, CNN recorded a consensus Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a 1-year average upside potential of 40.71%, based on 29 analysts following the stock.

Founded in 2006, Thermo Fisher Scientific Inc. (NYSE:TMO) is a life sciences and clinical research company. The company supplies analytical instruments, clinical development solutions, specialty diagnostics, and laboratory, pharmaceutical, and biotechnology services. Its headquarters is in Massachusetts.